Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colombia v Novartis: Do Big Prices Mean More Compulsory Licensing?

Executive Summary

After making noise about issuing a compulsory license, Colombia is now moving to force Novartis AG to lower its price for Glivec. The news could signal that pharmaceutical companies with high-priced medicines will face increasing threats to their intellectual property if they continue to charge big prices that middle- income countries cannot afford.

Advertisement

Related Content

Colombian Crack Down On Compulsory Licensing Under Attack
Novartis Takes On Colombia Over Glivec Pricing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel